1. Home
  2. NTAP vs EXAS Comparison

NTAP vs EXAS Comparison

Compare NTAP & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetApp Inc.

NTAP

NetApp Inc.

HOLD

Current Price

$95.38

Market Cap

19.7B

Sector

Technology

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$102.54

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTAP
EXAS
Founded
1992
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.7B
19.3B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NTAP
EXAS
Price
$95.38
$102.54
Analyst Decision
Buy
Buy
Analyst Count
14
19
Target Price
$121.15
$84.27
AVG Volume (30 Days)
2.6M
2.4M
Earning Date
02-26-2026
02-18-2026
Dividend Yield
2.13%
N/A
EPS Growth
5.78
N/A
EPS
5.75
N/A
Revenue
$6,637,000,000.00
$3,082,033,000.00
Revenue This Year
$4.99
$19.40
Revenue Next Year
$4.86
$13.54
P/E Ratio
$16.95
N/A
Revenue Growth
2.53
14.47
52 Week Low
$71.84
$38.81
52 Week High
$127.78
$102.66

Technical Indicators

Market Signals
Indicator
NTAP
EXAS
Relative Strength Index (RSI) 33.63 76.08
Support Level $97.16 $102.12
Resistance Level $100.58 $102.56
Average True Range (ATR) 2.93 0.29
MACD -0.24 -0.34
Stochastic Oscillator 9.17 77.86

Price Performance

Historical Comparison
NTAP
EXAS

About NTAP NetApp Inc.

NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of the cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services. Geographically, the company generates the majority of its revenue from the United States, Canada and Latin America (Americas).

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: